Navigation Links
Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent
Date:12/16/2009

AUSTIN, Texas, Dec. 16 /PRNewswire/ -- Savara, Inc., an inhalation drug delivery company, today announced that it has closed the second tranche in its Series A financing round, exceeding the targeted total raise amount of $1.4 million.

Funds raised in the Series A round will be utilized to continue the development of the NanoCluster technology.

"We now have the runway and resources to effectively demonstrate the scalability and performance of the NanoCluster technology," said Rob Neville, CEO of Savara.

The company also announced that it has received patent allowance from the United States Patent and Trademark Office (USPTO) for its core NanoCluster technology. The patent covers its unique formulation of inhalation particles that are composed of drug nanoparticles agglomerated together (US Patent No. 11/610,986).

"Allowance on our base patent is a significant milestone in our company's history. This proprietary position is strategically important to Savara and our partners as we utilize the NanoCluster technology to improve patient health in areas of unmet need," said Neville.

About Savara's NanoCluster Technology

Particle size is critical for pulmonary drug delivery, and the ability to obtain particle sizes in the range of 1-3 microns has the potential to improve the efficacy of existing and new drug therapies. Savara's NanoCluster technology utilizes nanotechnology to formulate high performance inhalation powder without the need for novel excipients or carrier particles. Savara's NanoClusters are modeled after naturally occurring aerosols, which are highly effective in reaching the peripheral lung. These aerodynamics enable high drug concentrations in specific regions of the lung, independent of the inhalation flow rate. Savara expects that NanoCluster's unique features will enable products that are currently difficult or impossible to develop using conventional inhalation powders.

About Savara, Inc.

Savara, Inc. (www.savarapharma.com) is a drug delivery company based in Austin, Texas and a member of the Austin Technology Incubator. Savara has an exclusive license to the NanoCluster technology from the University of Kansas. Savara's NanoCluster technology is currently available for evaluation and licensing.



    Contact Information

    Media:
    Ian Stone
    Russo Partners, LLC
    (619) 528-2220
    Ian.Stone@russopartnersllc.com

    Partners & Investors:
    Rob Neville
    (512) 961-1891 x2
    rob.neville@savarapharma.com


SOURCE Savara, Inc.


'/>"/>
SOURCE Savara, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioVascular Inc. Closes $10.87 Million Series C Financing
2. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
3. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
4. Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease
5. Curemark Closes Series A Financing
6. Blue Belt Technologies, Inc. Closes Series A Financing
7. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
8. American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008
9. Keraderm Closes on $2.5 Million Investment from NewVa Capital Partners, LP
10. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
11. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... ... , ... Apple Rehab Shelton Lakes , which specializes in the delivery ... as part of a disaster drill on October 3rd. , Apple Rehab participated with ... Manager, as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
Breaking Medicine News(10 mins):